Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Neil_Kumar
|
| gptkbp:focus |
genetic diseases
rare diseases |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Neil_Kumar
|
| gptkbp:fullName |
BridgeBio Pharma, Inc.
|
| gptkbp:headquartersLocation |
gptkb:Palo_Alto,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
BBIO
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US10806X1028
|
| gptkbp:notableProduct |
gptkb:acoramidis
gptkb:enzastaurin BBP-418 |
| gptkbp:numberOfEmployees |
over 400
|
| gptkbp:stockExchange |
gptkb:NASDAQ
gptkb:Russell_2000 |
| gptkbp:stockSymbol |
gptkb:BBIO
|
| gptkbp:subsidiary |
gptkb:Eidos_Therapeutics
|
| gptkbp:website |
https://bridgebio.com/
|
| gptkbp:bfsParent |
gptkb:BridgeBio_Pharma
|
| gptkbp:bfsLayer |
8
|